Table 7.
Univariate analysis for EFS and OS
| Variable (reference) | Comparator parameter | OR for EFS | 95% CI (P) | OR for OS | 95% CI (P) |
|---|---|---|---|---|---|
| Sex (male) | Female sex | 1.164 | 0.78-1.71 (.44) | 1.218 | 0.82-1.79 (.322) |
| T-ALL (TLC <100 × 109/L) | TLC >100 × 109/L | 0.789 | 0.337-1.846 (.585) | 0.799 | 0.342-1.87 (.606) |
| B-ALL (TLC <30 × 109/L) | TLC >30 × 109/L | 1.58 | 1.041-2.406 (.032) | 1.485 | 0.96-2.29 (.074) |
| CSF disease status (CSF involved) | CSF uninvolved | 0.548 | 0.303-0.99 (.046) | 0.532 | 0.29-0.96 (.037) |
| CNS stage (CNS stage 1) | CNS stage 3 | 2.9 | 1.42-5.94 (.004) | 2.814 | 1.37-5.75 (.005) |
| CSF FCM (CSF FCM+) | CSF FCM− | 0.51 | 0.24-1.09 (.084) | 0.515 | 0.24-1.1 (.08) |
| Postinduction MRD (negative status) | Positive status | 3.34 | 2.3-4.9 (<.001) | 3.413 | 2.28-5.09 (<.001) |
| MRD status beyond induction (negative status) | Positive status | 5.351 | 3.464-8.26 (<.001) | 4.88 | 3.12-7.65 (<.001) |
| WBC-based risk stratification* (B-ALL <30 × 109/L; T ALL <100 × 109/L) | Elevated WBC | 1.336 | 0.93-1.91 (.114) | 1.265 | 0.87-1.83 (.212) |
| Cytogenetic risk stratification† (standard risk) | High risk | 1.032 | 0.662-1.608 (.891) | 0.967 | 0.61-1.53 (.888) |
| Ploidy status (others apart from hypodiploidy) | Hypodiploid status | 0.757 | 0.39-1.44 (.40) | 0.73 | 0.37-1.42 (.356) |
| Risk groups‡ (standard risk) | High risk | 1.09 | 0.779-1.531 (.610) | 1.020 | 0.72-1.44 (.91) |
| Infections (development of infection) | Nondevelopment of infections | 0.68 | 0.49-0.943 (.02) | 0.65 | 0.46-0.91 (.011) |
*
Elevated WBC count: for B-ALL, >30 × 109/L; for T-ALL, >100 × 109/L.
†
High-risk cytogenetics: t(9;22), t(1;19), MLL translocation.
‡
High-risk subgroup: Patients with either elevated WBC count as per above (*) or high-risk cytogenetics or hypodiploidy.